Our Work
3D Bioprinted Models of Trophoblast Organoids
3D Microfluidics Models of Vascularised Tissue
Proteomic approaches to identify novel biomarkers of early- and late-onset preeclampsia
FKBPL signalling in placental development and growth
FKBPL targeting personalised treatment for preeclampsia
Mesenchymal stem/stromal cells as a new therapeutic option for preeclampsia
01
3D Bioprinted Trophoblast Organoids
This image shows the immunostaining of a growth factor receptor in a 3D bioprinted trophoblast organoid. Trophoblast cells in the placenta have a crucial role in establishing a connection between the mother and baby during pregnancy. This model can be used to investigate pregnancy and serious diseases such as preeclampsia.
​
Work by Mrs Claire Richards - PhD Candidate, Faculty of Science, School of Life Sciences, University of Technology Sydney, Australia
02
3D Microfluidics Models of Vascularised Tissue
Vascular network formation of human umbilical vein endothelial cells (HUVECs) co-cultured with human first trimester trophoblast cells in a 3D-microfluidic device. This 3D human placenta microfluidic model has been designed to investigate the endothelial and trophoblast cells' interaction in placental development and vascular dysfunction in preeclampsia.
​
Work by Ms Sahar Ghorbanpour - PhD Candidate, Faculty of Science, School of Life Sciences, University of Technology Sydney, Australia
03
Proteomic approaches to identify novel biomarkers of early- and late-onset preeclampsia
Proteomic analysis of the plasma samples was performed from women with early-onset preeclampsia (EOPE), late-onset preeclampsia (LOPE) and healthy pregnancies. (a) Principal component analysis (PCA) plot of proteomic data in EOPE, LOPE and healthy pregnancy groups. (b) Multigroup heatmap with hierarchical clustering dendrogram of proteomic data levels across EOPE, LOPE and healthy pregnancy groups.
​
Work by Mr Hao Chen - PhD Candidate, Faculty of Science & Centenary Institute, University of Technology Sydney, Australia
04
FKBPL targeting personalised treatment for preeclampsia
FKBPL as a critical angiogenesis regulator has shown to play an important role in the pathogenesis and diagnosis of preeclampsia. We are exploring FKBPL targeting therapies as potential personalised treatment for both prevention and treatment of preeclampsia in combination with FKBPL and CD44 as companion diagnostics.
